Cargando…
Development and Validation of a Reporter-Cell-Line-Based Bioassay for Therapeutic Soluble gp130-Fc
Soluble glycoprotein 130 kDa (sgp130)-Fc fusion protein, an innovative therapeutic bio-macromolecular drug specifically targeting IL-6 trans-signaling, proved to have good potential for application in the treatment of chronic inflammatory diseases. A simple and quick bioassay for sgp130-Fc was devel...
Autores principales: | Yu, Lei, Jia, Chuncui, Yao, Wenrong, Pei, Dening, Qin, Xi, Rao, Chunming, Wang, Junzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864625/ https://www.ncbi.nlm.nih.gov/pubmed/31731431 http://dx.doi.org/10.3390/molecules24213845 |
Ejemplares similares
-
Bioactivity Determination of a Therapeutic Recombinant Human Keratinocyte Growth Factor by a Validated Cell-based Bioassay
por: Yao, Wenrong, et al.
Publicado: (2019) -
Responsive Cells for rhEGF bioassay Obtained through Screening of a CRISPR/Cas9 Library
por: Qin, Xi, et al.
Publicado: (2019) -
Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein
por: Pei, Dening, et al.
Publicado: (2019) -
Exclusive inhibition of IL-6 trans-signaling by soluble gp130(FlyR)Fc
por: Berg, Anna F., et al.
Publicado: (2021) -
Identification of a Recombinant Human Interleukin-12 (rhIL-12) Fragment in Non-Reduced SDS-PAGE
por: Yu, Lei, et al.
Publicado: (2019)